AT7867 | Akt Inhibitor | AmBeed-信号通路专用抑制剂

首页 / / / Akt / AT7867

AT7867 98%

货号：A151784

AT7867是一种ATP竞争性抑制剂，靶向Akt1/2/3和p70S6K/PKA，IC50分别为32nM/17nM/47nM和85nM/20nM，几乎不对AGC激酶家族以外的激酶具有抑制作用。

AT7867 化学结构
CAS号：857531-00-1

AT7867 3D分子结构
CAS号：857531-00-1

规格	价格	库存	数量
50μL*10mM(DMSO)	￥99随货￥69	现货	- +
10mM*1mL(DMSO)	￥562	现货	- +
1mg	￥302	现货	- +
2mg	￥451	现货	- +
5mg	￥756	现货	- +
10mg	￥1008	现货	- +
50mg	￥2079	咨询
100mg	￥3492	咨询
1g	￥15428	咨询

购物车0 收藏询单

sales@ambeed.cn tech@ambeed.cn 400-920-2911 产品手册产品订购技术咨询
快速发货顺丰冷链运输，1-2 天到达

品质保证

技术支持

免费溶解

AT7867 纯度/质量文件产品仅供科研

货号：A151784 标准纯度： 98% 产品说明书

批次查询：批次纯度: COA NMR HPLC CNMR LC-MS

全球学术期刊中引用的产品: • ACS Appl. Nano Mater., 2025. Ambeed. [ A188026 ]; • Eur. J. Clin. Microbiol. Infect. Dis., 2025. Ambeed. [ A151161 ]; • JJC, 2025, 20(Special Issue)): 27-39. Ambeed. [ A713856 ]; • bioRxiv, 2025. Ambeed. [ A538667 , A714873 , A126729 , A126049 , A446054 ]; • Nature Communications, 2025, 16, 1871. Ambeed. [ A508148 ]; 更多 >

Akt 亚型比较

产品名称	Akt ↓ ↑	Akt1 ↓ ↑	Akt2 ↓ ↑	Akt3 ↓ ↑	其他靶点	纯度
Honokiol	✔				MEK	98%
PF-04691502	++++ P-Akt (S473), IC50: 3.8 nM P-Akt (T308), IC50: 7.5 nM					98+%
PHT-427	+ Akt, Ki: 2.7 μM					99%+
Deguelin	✔				PI3K	99%+
TIC10 isomer	✔				ERK	98+%
Perifosine	+ Akt, IC50: 4.7 μM					98%
Miltefosine	✔				PKC,PI3K	98%
Triciribine	+ Akt, IC50: 130 nM					99%+
Uprosertib		+ Akt1, IC50: 180 nM	+ Akt2, IC50: 328 nM	++ Akt3, IC50: 38 nM		99%+
Afuresertib		++++ Akt1, Ki: 0.08 nM	++++ Akt2, Ki: 2 nM	++++ Akt3, Ki: 2.6 nM		99%+
Miransertib		++++ Akt1, IC50: 5 nM	++++ Akt2, IC50: 4.5 nM	++ Akt3, IC50: 16 nM		98+%
GSK-690693		++++ Akt1, IC50: 2 nM	+++ Akt2, IC50: 13 nM	+++ Akt3, IC50: 9 nM		99%+
AT7867		++ Akt1, IC50: 32 nM	++ Akt2, IC50: 17 nM	++ Akt3, IC50: 47 nM	PKA	99%+
AKT inhibitor VIII		++ Akt1, IC50: 58 nM	+ Akt2, IC50: 210 nM	+ Akt3, IC50: 2119 nM		98+%
MK-2206 2HCl		+++ Akt1, IC50: 8 nM	+++ Akt2, IC50: 12 nM	+ Akt3, IC50: 65 nM		99%+
Ipatasertib		++++ Akt1, IC50: 5 nM	++ Akt2, IC50: 18 nM	+++ Akt3, IC50: 8 nM		99%+
AT13148		++ Akt1, IC50: 38 nM	+ Akt2, IC50: 402 nM	++ Akt3, IC50: 50 nM	PKA	95%
Capivasertib		++++ Akt1, IC50: 3 nM	+++ Akt2, IC50: 8 nM	+++ Akt3, IC50: 8 nM		99%+
A-674563 HCl		+++ Akt1, Ki: 11 nM			PKA	99%
CCT128930			+++ Akt2, IC50: 6 nM		PKA	95%
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

AT7867 生物活性

靶点	Akt3 Akt3, IC50:47 nM Akt1 Akt1, IC50:32 nM Akt2 Akt2, IC50:17 nM
描述	The protein kinase B (AKT) is a serine/threonine kinase that plays a pivotal role in tumor cell growth, malignant transformation, and chemoresistance. AT7867 is a potent inhibitor of three isoforms of AKT (AKT1, AKT2, and AKT3), the downstream kinase p70S6K, and PKA with IC50 values of 32, 17, 47, 20, and 85nM, respectively. AT7867 potently binds to AK2 in a ATP-competitive manner with a K_i value of 18nM. AT7867 inhibited the proliferation of multiple human cancer cell lines, including MES-SA, MDA-MB-468, MCF-7, U87MG, PC-3, DU145, HCT116, and HT29, with IC50 values in the range of 0.9–12µM. It also exerts an equipotent inhibitory effect on GSK3β phosphorylation across multiple cancer cell lines with IC50 values ranging from 2–4μM. The treatment of U87MG human glioblastoma cells with AT7867 induces apoptosis and suppressed AKT signaling in a concentration- and time-dependent manner. The administration of AT7867 (90mg/kg p.o. or 20mg/kg i.p.) significantly inhibited the phosphorylation of GSK3β and S6RP in mice bearing MES-SA tumors at 2 and 6 h following treatment. Mice treated with AT7867 at 20mg/kg i.p. showed a T/C ratio (tumor volume in treated mice versus control mice) of 0.37 on day 12. The T/C ratio in the group administered with AT7867 at 90mg/kg p.o. was 0.38 on day 10. ^[2]
作用机制	AT7867 binds to the ATP site of AK2, forming electrostatic interactions with the ribose site, hydrogen-bonding interactions with the kinase hinge region, and hydrophobic contacts with a lipophilic pocket in the glycine-rich loop.^[2]

AT7867 参考文献

[1]Grimshaw KM, Hunter LJ, et al. AT7867 is a potent and oral inhibitor of AKT and p70 S6 kinase that induces pharmacodynamic changes and inhibits human tumor xenograft growth. Mol Cancer Ther. 2010 May;9(5):1100-10.

[2]Grimshaw KM, Hunter LJ, Yap TA, et al. AT7867 is a potent and oral inhibitor of AKT and p70 S6 kinase that induces pharmacodynamic changes and inhibits human tumor xenograft growth. Mol Cancer Ther. 2010;9(5):1100‐1110. doi:10.1158/1535-7163.MCT-09-0986

AT7867 实验方案

计算器

存储液制备

1mg

5mg

10mg

1 mM

5 mM

10 mM

2.96mL

0.59mL

0.30mL

14.80mL

2.96mL

1.48mL

29.60mL

5.92mL

2.96mL

AT7867 技术信息

CAS号	857531-00-1
分子式	C₂₀H₂₀ClN₃
分子量	337.846

别名
运输	蓝冰

存储条件

In solvent -20°C:3-6个月-80°C:12个月

Pure form Keep in dark place,Sealed in dry,Store in freezer, under -20°C

溶解方案

细胞实验：

DMSO: 50 mg/mL(148 mM)，配合低频超声，并水浴加热至45℃助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

动物实验：请根据您的动物给药指南选择适当的溶解方案。
以下溶解方案都请先按照体外实验的方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议现用现配，当天使用；以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

方案一

方案二

动物实验配方

AT7867 98%

AT7867 纯度/质量文件产品仅供科研

全球学术期刊中引用的产品

AT7867 质控信息

AT7867 生物活性

AT7867 参考文献

AT7867 实验方案

AT7867 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Akt3	Akt3, IC50:47 nM
Akt1	Akt1, IC50:32 nM
Akt2	Akt2, IC50:17 nM

AT7867 98%

AT7867 纯度/质量文件 产品仅供科研

全球学术期刊中引用的产品

AT7867 质控信息

AT7867 生物活性

AT7867 参考文献

AT7867 实验方案

AT7867 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

请登录您的专属账户

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

AT7867 纯度/质量文件产品仅供科研